These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study. Ancy I; Sivanandam M; Kumaradhas P J Biomol Struct Dyn; 2021 Sep; 39(15):5368-5375. PubMed ID: 32627689 [TBL] [Abstract][Full Text] [Related]
5. Identification of SARS-CoV-2 main protease inhibitors from FDA-approved drugs by artificial intelligence-supported activity prediction system. Komatsu H; Tanaka T; Ye Z; Ikeda K; Matsuzaki T; Yasugi M; Hosoda M J Biomol Struct Dyn; 2023 Mar; 41(5):1767-1775. PubMed ID: 34984963 [TBL] [Abstract][Full Text] [Related]
6. Targeting two potential sites of SARS-CoV-2 main protease through computational drug repurposing. Prakash A; Borkotoky S; Dubey VK J Biomol Struct Dyn; 2023 Apr; 41(7):3014-3024. PubMed ID: 35266856 [TBL] [Abstract][Full Text] [Related]
7. Synthetic flavonoids as potential antiviral agents against SARS-CoV-2 main protease. Batool F; Mughal EU; Zia K; Sadiq A; Naeem N; Javid A; Ul-Haq Z; Saeed M J Biomol Struct Dyn; 2022 May; 40(8):3777-3788. PubMed ID: 33251983 [TBL] [Abstract][Full Text] [Related]
8. Targeting allosteric pockets of SARS-CoV-2 main protease M Bhat ZA; Chitara D; Iqbal J; Sanjeev BS; Madhumalar A J Biomol Struct Dyn; 2022 Sep; 40(14):6603-6618. PubMed ID: 33645457 [TBL] [Abstract][Full Text] [Related]
9. A higher flexibility at the SARS-CoV-2 main protease active site compared to SARS-CoV and its potentialities for new inhibitor virtual screening targeting multi-conformers. Rocha REO; Chaves EJF; Fischer PHC; Costa LSC; Grillo IB; da Cruz LEG; Guedes FC; da Silveira CH; Scotti MT; Camargo AD; Machado KS; Werhli AV; Ferreira RS; Rocha GB; de Lima LHF J Biomol Struct Dyn; 2022; 40(19):9214-9234. PubMed ID: 33970798 [TBL] [Abstract][Full Text] [Related]
10. Computational discovery of small drug-like compounds as potential inhibitors of SARS-CoV-2 main protease. Andrianov AM; Kornoushenko YV; Karpenko AD; Bosko IP; Tuzikov AV J Biomol Struct Dyn; 2021 Sep; 39(15):5779-5791. PubMed ID: 32662333 [TBL] [Abstract][Full Text] [Related]
11. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. Kumar Y; Singh H; Patel CN J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274 [TBL] [Abstract][Full Text] [Related]
12. Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with M J A; Francis D; C S S; K G A; C S; Variyar EJ J Biomol Struct Dyn; 2022 Jan; 40(1):325-336. PubMed ID: 32873185 [TBL] [Abstract][Full Text] [Related]
13. Repurposing of US-FDA approved drugs against SARS-CoV-2 main protease (M Khan AM; Atia-Tul-Wahab ; Farooq S; Ullah A; Choudhary MI Int J Biol Macromol; 2023 Apr; 234():123540. PubMed ID: 36740128 [TBL] [Abstract][Full Text] [Related]
14. Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents. Ahmed MZ; Zia Q; Haque A; Alqahtani AS; Almarfadi OM; Banawas S; Alqahtani MS; Ameta KL; Haque S J Infect Public Health; 2021 May; 14(5):611-619. PubMed ID: 33866129 [TBL] [Abstract][Full Text] [Related]
15. Computational basis of SARS-CoV 2 main protease inhibition: an insight from molecular dynamics simulation based findings. Avti P; Chauhan A; Shekhar N; Prajapat M; Sarma P; Kaur H; Bhattacharyya A; Kumar S; Prakash A; Sharma S; Medhi B J Biomol Struct Dyn; 2022; 40(19):8894-8904. PubMed ID: 33998950 [TBL] [Abstract][Full Text] [Related]